Epcoritamab is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from …

2023年11月17日 · What is epcoritamab? Epcoritamab is used to treat certain types of lymphoma (a cancer of the lymphatic system) in adults whose cancer has returned or did not respond to …

2022年12月22日 · Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Single …

2023年4月20日 · Purpose: Epcoritamab is a subcutaneously administered CD3xCD20 T-cell-engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B …

2023年6月7日 · Epcoritamab is a prescription medication used for the treatment of B-cell lymphoma. Epcoritamab is available under the following different brand names: Epkinly, …

Epcoritamab is a humanized immunoglobulin G1 (IgG1) manufactured in Chinese hamster ovary cells. It is a T-cell engaging bispecific antibody that binds to the T-cell antigen CD3 and the B …

Epcoritamab-bysp is a type of targeted therapy drug called a bispecific T-cell engager (BiTE). FDA label information for this drug is available at DailyMed. Epcoritamab-bysp is approved to …

Epcoritamab is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise …

The active substance in Tepkinly, epcoritamab, is an antibody (a type of protein) which is described as ‘bispecific’ because it recognises and attaches to two targets simultaneously: …

Epcoritamab is also called Tepkinly®. It is a type of targeted therapy drug called a monoclonal antibody. It is also called a bi-specific antibody. Epcoritamab is used to treat diffuse large B …